Aquestive Therapeutics Inc(AQST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 22 at 7:30 PM ET (Korea 9/23 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.65 | Insider Own | 5.28% | Shs Outstand | 125.5M | Perf Week | 2.91% |
| Market Cap | 0.62B | Forward P/E | - | EPS next Y | -1.81% | Insider Trans | -2.1% | Shs Float | 118.9M | Perf Month | 6.22% |
| Enterprise Value | 0.67B | PEG | - | EPS next Q | -0.12 | Inst Own | 55.29% | Short Float | 21.43% | Perf Quarter | -1.59% |
| Income | -0.08B | P/S | 11.49 | EPS this Y | 37.04% | Inst Trans | 0.1% | Short Ratio | 9.15 | Perf Half Y | 25.95% |
| Sales | 0.05B | P/B | - | EPS next 5Y | 21.87% | ROA | -69.29% | Short Interest | 25.48M | Perf YTD | -23.37% |
| Book/sh | -0.45 | P/C | 6.31 | EPS past 3/5Y | 11.13% 13.92% | ROE | - | 52W High | -34.44% ($7.55) | Perf Year | -4.26% |
| Cash/sh | 0.78 | P/FCF | - | Sales past 3/5Y | -2.24% -0.58% | ROIC | -86.35% | 52W Low | 68.94% ($2.93) | Perf 3Y | 213.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 5.86% | Gross Margin | 67.04% | Volatility(W/M) | 4.93% 5.27% | Perf 5Y | 11.74% |
| Dividend TTM | - | EV/Sales | 12.42 | Sales Y/Y TTM | 22.56% | Oper. Margin | -97.52% | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.74 | EPS Q/Q | -34.09% | Profit Margin | -144.63% | RSI (14) | 55.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.19 | Sales Q/Q | 38.15% | SMA20 | -1.7% ($5.04) | Beta | 1.47 | Target Price | $9.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/11 | SMA50 | 11.3% ($4.45) | Rel Volume | 0.89 | Prev Close | $4.78 |
| Employees | 147 | LT Debt/Eq | - | EPS/Sales Surpr. | -71.43% 21.03% | SMA200 | 12.38% ($4.4) | Avg Volume(3M) | 2.78M | Price | $4.95 |
| IPO | 2018/7/25 | Option/Short | Yes/Yes | Trades | 9030 | Volume | 2,478,389 | Change | 3.56% |
Company
AQST is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Aquestive Therapeutics is a pharmaceutical company that develops and commercializes treatments for central nervous system disorders and allergic reactions based on its proprietary PharmFilm oral-soluble film technology. Founded in 2004 and headquartered in the United States, the company pursues a differentiated approach to needle-free drug delivery, including a film-based drug portfolio for seizures, epilepsy, and addiction, as well as a sublingual epinephrine film for anaphylaxis. Its US Nasdaq-listed ticker is AQST.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
AQST has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +213.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 55.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SURI 0.01%
XPH 0.01%
PILL 0.01%
FSCC 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $621M.
AQST $621M PER -
TAK $60B PER -
TEVA $46B PER 65.9
HLN $41B PER 19.0
FAQ
What kind of company is AQST?
AQST belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AQST?
The market cap of AQST is approximately $621M, ranking 3,038 within its sector.
What is the 52-week high and low for AQST?
AQST has recorded a 52-week high of $7.55 and a low of $2.93.
